Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 84,011 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: therapy Clear all

Conditions: Obesity, Childhood, Metabolic Syndrome
Interventions: FIT, Home-Based Family Support; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Alzheimer's Disease
Interventions: SUVN-502, Placebo, Donepezil, Memantine; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 71
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more

Conditions: Stretch Marks, Striae Distensae, Cosmetic Appearance of Stretch Marks
Interventions: Placebo Vehicle Cream, Centella Asiatica Cream; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Asthma
Interventions: Bronchoscopic; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Cyclosporine, Methotrexate, Photopheresis, Mycofenolate mofetil, Pentostatin, allogeneic bone marrow, peripheral blood stem cell, Total body irradiation; Drug · Procedure · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 6
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more

Conditions: Hernia, Ventral, Weight Loss
Interventions: Prehabilitation, Standard counseling; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acquired Hemophilia A
Interventions: emicizumab; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 16
States / cities: San Diego, California • Washington D.C., District of Columbia • Atlanta, Georgia + 13 more

Conditions: Nutrition
Interventions: Antibiotic (metronidazole and ciprofloxacin)/probiotic; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Adavosertib, Olaparib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay, Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Cognition Disorders
Interventions: Not listed
Lead sponsor: University of Southern California; Other
Eligibility: 65 Years to 85 Years
Enrollment: 538 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2023
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 32 more

Conditions: Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions: OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Rumination Disorder
Interventions: CBT-RD; Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 10 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Low-fat diet; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: College Student Drinking
Interventions: Personalized Normative Feedback (PNF), Self-Monitoring (SM), Web-BASICS, Health Promotion Consultation, M-Bridge Online Health Coach; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 21 Years
Enrollment: 891 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Interventions: retifanlimab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 8
States / cities: Scottsdale, Arizona • Grand Rapids, Michigan • New Brunswick, New Jersey + 4 more

Conditions: HIV-1
Interventions: OZ1 transduced cells; Genetic
Lead sponsor: Janssen-Cilag Pty Ltd; Industry
Eligibility: Not listed
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • New York, New York

Conditions: Vomiting
Interventions: Functional Living Index - Emesis; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bronchopulmonary Dysplasia
Interventions: Infasurf surfactant (ONY, Inc.), Sham (No Treatment); Drug
Lead sponsor: Roberta Ballard; Other
Eligibility: 7 Days to 14 Days
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 21
States / cities: Little Rock, Arkansas • Berkeley, California • Oakland, California + 15 more

Conditions: Headache
Interventions: Metoclopramide, Diphenhydramine, Codeine; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
Interventions: Panitumumab, Bevacizumab, mFOLFOX6; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 63
States / cities: Birmingham, Alabama • Huntsville, Alabama • Berkeley, California + 59 more

Conditions: Influenza
Interventions: Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Huntsville, Alabama • Melbourne, Florida • Peoria, Illinois + 2 more

Conditions: Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies, Vascular Anomaly
Interventions: Trametinib; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Months to 30 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mindfulness, Sense of Belonging
Interventions: Meditation, Yoga; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

FIT Families Multicomponent Obesity Intervention for African American Adolescents

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks

Inflammatory Processes in the Airway of Asthmatics With Persistent Bronchial Hyperreactivity

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Modifying Risk in Ventral Hernia Patients

Emicizumab in Patients With Acquired Hemophilia A

Gut Flora Dependent Metabolism of Dietary Phosphatidylcholine and Cardiovascular Disease

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women

Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

A Study of Cognitive-Behavioral Therapy for Rumination Disorder

Low Fat Diet for Fatigue in MS

Adaptive Preventive Intervention for College Alcohol Use

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial

Observational Study of Delayed Nausea and Vomiting

Trial of Late Surfactant for Prevention of Bronchopulmonary Dysplasia

A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

Belongingness in Nursing Through Mindfulness - BEING Mindful: A Pilot Study